Navigating Centene Aimovig Prior Authorization for Migraine Treatment

Aimovig (Erenumab) in Migraine Management

Aimovig (erenumab) is a CGRP receptor antagonist indicated for the preventive treatment of chronic migraine and episodic migraine. As a specialty injectable, its coverage typically involves a prior authorization process, often requiring documented trials and failures of other generic preventive migraine therapies as part of step therapy protocols.

Centene's Federated Prior Authorization Landscape

Centene Corporation operates as a federation of state-licensed subsidiaries, including prominent brands like Ambetter (ACA marketplace), Wellcare (Medicare), and various state Medicaid managed care plans (e.g., Fidelis Care, Health Net, Meridian, Sunshine Health, Superior HealthPlan). Prior authorization processes, provider portals, and clinical policies for Aimovig are specific to each subsidiary and plan type, rather than a single corporate standard.

Aimovig Prior Authorization Submission Channels for Centene Plans

• **Pharmacy Benefit (Retail/Specialty Pharmacy)**: If Aimovig is covered under the pharmacy benefit, submissions typically route through Envolve Pharmacy Solutions (Centene's in-house PBM) and industry ePA platforms like CoverMyMeds or Surescripts.
• **Medical Benefit**: For medical benefit coverage, prior authorization requests are submitted via the specific Centene subsidiary's provider portal. X12 278 transactions are generally accepted via clearinghouses for impacted medical benefit procedures.
• PA criteria and formularies for Aimovig, including specific step therapy requirements and quantity limits, vary significantly by the Centene subsidiary and the member's plan type (e.g., Medicaid, Medicare Advantage, Ambetter).

Understanding Aimovig Coverage Criteria and Utilization Management

Centene subsidiaries publish their specific clinical policies and coverage determinations for Aimovig, including step therapy and quantity limits, through their respective provider portals. These policies may incorporate criteria from vendors like InterQual for medical necessity review. For Medicaid lines, subsidiary policies must align with, and cannot be more restrictive than, the contracting state Medicaid agency's coverage rules. Wellcare and Allwell Medicare Advantage plans follow CMS-mandated guidelines.

Prior Authorization Turnaround Times and Regulatory Impact

Aimovig PA turnaround times with Centene are dictated by the specific plan type. Medicaid managed care lines adhere to state Medicaid agency mandates, which vary significantly by state. Wellcare and Allwell Medicare Advantage plans follow CMS-mandated organization determination timeframes (14 calendar days standard, 72 hours expedited). Ambetter ACA marketplace plans follow state insurance regulations. All Centene's impacted payer lines (Medicaid, MA, CHIP, QHP-on-FFM) are subject to CMS-0057-F, which mandates 72-hour standard and 24-hour expedited PA decision timeframes on a phased compliance timeline.

Common Denial Reasons and Appeal Pathways for Aimovig

• **Medical Necessity / Insufficient Documentation**: Lack of clinical evidence demonstrating Aimovig meets specific criteria or inadequate supporting clinical notes.
• **Step Therapy Non-Compliance**: Failure to document a trial and failure of required generic preventive migraine therapies.
• **Benefit Exclusion / Non-Formulary**: Aimovig is not covered under the specific plan's formulary or benefit design for that member.
• **Prior Authorization Not Obtained**: Services rendered without securing the necessary prior authorization.
• **Appeal Pathways**: Appeals follow subsidiary-specific processes. Medicaid managed care appeals adhere to state Medicaid agency's mandated appeal and grievance structures, including state fair-hearing rights. Medicare Advantage lines follow the CMS-mandated 5-level appeal structure for organization determinations.